Strativa Pharmaceuticals, Discontinuation of the Development Program for Pafuramidine

February 25, 2008 – Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE:PRX) announced that its development partner, Immtech Pharmaceuticals, Inc. (AMEX: IMM) has chosen to discontinue the development program for pafuramidine maleate, an investigative therapy...
...receiving recommendations from the Data Safety Monitoring Board, the Steering Committee for the pneumocystis pneumonia (PCP) study and others, and in consultation with the US Food and Drug Administration (FDA) and Immtech’s licensing partners, including Strativa, Immtech has chosen to discontinue the development program for pafuramidine... Par Pharmaceutical's Press Release-

The SFDA of the PRC Grants Immtech Fast Track Status

September 27, 2007 - Immtech Pharmaceuticals, Inc. (AMEX:IMM) announced that the State Food and Drug Administration of the People’s Republic of China (SFDA) has granted Immtech’s application Fast Track Status for conducting a Phase III clinical trial with pafuramidine, the Company’s oral drug candidate for the treatment of Pneumocystis pneumonia (PCP)... Immtech's Press Rease [PDF] -